Who are PQ (0.75)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PQ supervised, PQ unsupervised, Tafenoquine prophylaxis, Supervised primaquine treatment, Unsupervised primaquine treatment, High dose ultra short Primaquine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pq-0-75.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

PQ (0.75) — Competitive Intelligence Brief

PQ (0.75) (PQ (0.75)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 8-aminoquinoline antimalarial. Area: Infectious Disease / Parasitology.

phase 3 8-aminoquinoline antimalarial Plasmodium hypnozoite (liver stage parasite) Infectious Disease / Parasitology Small molecule Live · refreshed every 30 min

Target snapshot

PQ (0.75) (PQ (0.75)) — London School of Hygiene and Tropical Medicine. PQ is a primaquine analog that acts as an 8-aminoquinoline antimalarial targeting the hypnozoite stage of Plasmodium parasites in the liver.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PQ (0.75) TARGET	PQ (0.75)	London School of Hygiene and Tropical Medicine	phase 3	8-aminoquinoline antimalarial	Plasmodium hypnozoite (liver stage parasite)
PQ supervised	PQ supervised	Menzies School of Health Research	marketed	8-aminoquinoline antimalarial	Plasmodium hypnozoites (mechanism not fully elucidated at molecular level)
PQ unsupervised	PQ unsupervised	Menzies School of Health Research	marketed	8-aminoquinoline antimalarial	Plasmodium hypnozoite mitochondria
Tafenoquine prophylaxis	Tafenoquine prophylaxis	Naval Medical Research Center	marketed	8-aminoquinoline antimalarial	Plasmodium mitochondrial electron transport chain
Supervised primaquine treatment	Supervised primaquine treatment	Menzies School of Health Research	marketed	8-aminoquinoline antimalarial	Plasmodium parasite mitochondria and DNA
Unsupervised primaquine treatment	Unsupervised primaquine treatment	Menzies School of Health Research	marketed	8-aminoquinoline antimalarial	Malaria parasite mitochondria and DNA (indirect via oxidative stress)
High dose ultra short Primaquine	High dose ultra short Primaquine	Menzies School of Health Research	phase 3	8-aminoquinoline antimalarial	Malaria parasite (Plasmodium spp.) — mechanism involves oxidative stress generation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (8-aminoquinoline antimalarial class)

Menzies School of Health Research · 5 drugs in this class
London School of Hygiene and Tropical Medicine · 2 drugs in this class
Naval Medical Research Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PQ (0.75) — Competitive Intelligence Brief. https://druglandscape.com/ci/pq-0-75. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab